A Case of the Successful Application of a “Device to Remote Transfer of Information from a Drug to the Human Body” in the Treatment of Multiple Sclerosis

Abstract

Laser therapy is a type of physiotherapy based on the use of optical radiation, the source of which is a laser. The average powers of physiotherapeutic lasers are most often in the range of 1-100 mW and they are used in almost all areas of modern medicine. According to the Spanish World Laser Therapeutic Association, the optimal energy parameters of low-level laser radiation are recommended for its application. We could not find data on using a “device for remote transfer of information from a drug to a human body,” where the light source is a laser device with an extremely low energy level in treating severe neurological disease -multiple sclerosis. This report describes the results of a study using a “device to remote transfer of information from a drug to the human body”(Russian patent), where a laser with a power of up to 5 mV was used as a light source, and the drugs erythromycin and acyclovir were used to treat a 52-year-old Caucasian female musician with Multiple Sclerosis (MS). The applied exposure has led to the suppression of the activity of the disease, preventing the growth of neurological manifestations of the disease and reducing the appearance of demyelinating lesions in the patient’s brain with MS.

Keywords

Multiply sclerosis; Medicament testing; Device for remote transfer of information from a drug to a human body; Erythromycin; Acyclovir

Introduction

Multiply Sclerosis (MS) is a chronic autoimmune inflammatory disease characterized by demyelination and central nervous system axonal degeneration [1]. The MS treatment has two aspects: Immunomodulatory therapy for the underlying immune disorder and therapies to relieve or modify MS symptoms. These agents appear to slow disability progression and reduce the accumulation of lesions within the brain and spinal cord [2,3]. Low-Level Laser (light) Therapy (LLLT) is traditionally used to reduce pain, inflammation, and edema, to promote wound, deeper tissues, and nerve healing, and to prevent tissue damage [4].

Animal experiments using low power lasers with experimental MS are being conducted and have shown a promising result [5]. However, we were unable to find data on the use of the unusual application of laser radiation with an extremely low energy level for the treatment of a patient with MS, and this is the first case of treating a patient with MS using the drugs erythromycin and acyclovir placed in a field generated by low-level laser radiation transmitted through a spiral light guide-emitter, which led to the suppression of activity disease, preventing the growth of neurological manifestations of the disease and reducing the occurrence of the appearance of demyelinating lesions in a patient with MS.

Case Representation

In January 2017, a 52-year-old Caucasian female musician presented with complaints of fatigue that increased throughout the day, weakness when walking, constant headaches, dizziness, stiffness in the arms and legs, mainly on the right side, unsteadiness of gait, tingling, and numbness in four limbs, inability to play the piano, problems with bladder control and insomnia.

In 2009, the patient began to complain for the first time of weakness in the left arm and leg, sudden dizziness attacks, severe fatigue, and a tingling sensation in the palms of both hands. In December 2013, during her subsequent hospitalization with complaints of paralysis of the right arm and severe weakness in the right leg, taking into account MRI data of the brain and based on the criteria of McDonald, the diagnosis of multiple sclerosis, relapsing-remitting form, was made for the first time.

According to the EDSS disability scale, the patient's condition was rated 7,5 points. The high-dose cortisone treatment (methylprednisolone 1 g intravenously for five days) was initiated with progressive symptom reduction. In 2014, the patient received Copaxone (Teva Pharmaceutical Industries, Israel) 1.0 ml twice during the year for 54 injections. She continued to take oral prednisolone at the dose of 10 mg every day.

In January 2017, she was admitted to the Out-Patient Department of the Institute of Virology with above-described complaints. Her medical history included chronic tonsillitis and paranasal sinusitis with frequent exacerbations from early childhood. Her family history was unremarkable.

Upon examination, the patient’s vital signs were typical. The neurological examination revealed horizontal gaze-evoked nystagmus and smoothness of the left nasolabial fold. The patient had upper-level motor weakness in her four extremities scale scores of 3.0 b proximally and 3.0 b distally with spasticity, hyperreflexia, and pathological reflexes of Babinski in both lower limbs. She had the following cerebellar signs: Incoordination (dysdiadochokinesia, problems with heel-to-shin test), rapid repeating movements, ataxic gait, loss of balance, and following sensory impairments: Paresthesia, numbness, positive Romberg's test. Cognitive and emotional abnormalities in our patient included a fluctuating hyperactive state with mild agitation.

Results

The blood test revealed positive results for Cytomegalovirus (IgG Ab) and HSV ½ (IgG Ab). The pharyngeal swab revealed the presence of β-hemolytic Streptococcus. Due to objective causes, we could not perform an evoked potential test and Cerebrospinal Fluid (CSF) examination for the presence of oligoclonal bands.

Considering the patient’s condition and the lack of effect from traditional therapy, the patient was offered non-invasive Electropuncture diagnostics (EAV) to conduct Medicament Testing (MT) and the subsequent use of the “device for remote transfer of information from a drug to the human body” (DTI) [6]. The study was conducted following the principles of the Declaration of Helsinki and was approved by the Ethical Committee of the Ministry of Health of R. Uzbekistan (№ 12/8-1500 from 01/03/2017). The patient signed the informed consent to participate in the study.

To measure the level of electrical impedance at the Acupuncture Points (AP), we selected the following acupuncture points (measurement points (MP), Voll): Ly1, Ly3, Kr8a, Ne1, Ne1b*, Ne2, Ne3, Ne4. Abbreviations of the meridians are the Ly-lymphatic system, the Kr-circulation meridian, and the Ne-nervous system [7]. For medicament testing, taking into account the medical history of our patient and the results of the pharyngeal swab, the nosode of Streptococcus spp. in 30 C dilution was selected and erythromycin (100 mg tablets) was chosen. A detailed description of the method has been described previously [6]. The results of EAV readings are presented in (Table 1).

Table 1. Results of medicament testing before the first session of exposure.

Pre-test readings are given as the final result of the EAV device readings obtained after the indicator drop [6]. EAV post-test readings reflect the results obtained after medicament testing using the nosode of Streptococcus spp. and Erythromycin at the specified measuring points. As can be seen from the presented data, a positive response to medicament testing was obtained at four measuring points: Ly1, Ly3, Kr8a, and Ne3. To carry out therapy for the patient, it was suggested to use a DTI in the field in which erythromycin tablets would be placed. Figure 1 shows the device’s scheme used in the study (Patent of the Russian Federation) [8].

Figure 1: Scheme of the device used in the study.

According to the recommendations of Dr. Voll, the measurement points with a positive response to medicament testing are associated with the following internal organs [7]:

1. Ly1-palatine tonsil, including peri- and retro-tonsillar space with lymph drainage to the deep lymph nodes of the neck.

2. Ly3-lymph drainage from the mucous membranes of the nasal cavity and paranasal sinuses.

3. Kr8a-deep cervical lymph nodes.

4. Ne3-brain stem and cerebrum.

The patient received a full explanation regarding the DTI, as well as regarding the procedure itself: She is placed on a couch in the supine position and a cylinder (emitter) with erythromycin (tablets) put into it is settled on the body surface (non-invasive access) over the projection of some organs. At first, the laser device is switched on. The duration of the procedure is up to 30 minutes (the time is set individually, for the time established according to the exposure table; if necessary, under the control of the dynamics of the relevant physiological or biochemical indicators (pulse rate, blood pressure, etc.)). After the completion of the exposure, the laser device is switched off. Thus, the patient does not receive the drug traditionally, but with the help of DTI, the properties of the drug placed in the DTI area at the time of exposure are transferred into her body. In her case, this effect makes it possible to freely and safely reach certain areas of her body where traditional access for medications is complex and requires special conditions (for example, the brain).Thus, the following organs were planned to be exposed: Palatine tonsils (D, S), paranasal sinuses (D, S), deep cervical lymph nodes (D, S), and brain (D, S).

The procedure began on 02.02.2017. During the first session of exposure, the erythromycin (100 mg) was placed into the emitter and above the projection of the palatine tonsils (D, S, sequentially). Then, the emitter was closed with a cover, and the laser apparatus was switched on. The procedure lasted 30 minutes, and the laser apparatus was switched off. The patient did not feel the moment the device was turned on and off and was not warned about this. On the patient’s next visit in 10 days, we repeated the procedure described above and applied an emitter of the DTI above the projection of the paranasal sinuses (D, S, sequentially). The procedures were repeated every ten days, and on her last visit on March 3, 2017, the emitter of the DTI was located above the brain projection. For this purpose, the patient was placed in a lying position on her side (D, S), and the exposure was carried out separately over the projection of different parts of the brain: Frontal lobe, temporal zone, parietal zone, occipital zone, and cerebellum. The patient continued to receive prednisolone at a dose of 10 mg daily. On March 23, 2017, the patient’s condition improved significantly: Fatigue and weakness when walking disappeared, headache and dizziness stopped, and gait improved. The neurological examination data did not change. She ceased taking prednisolone in May 2017.

At the time of stopping prednisolone, the following complaints were presented: Slightly expressed stiffness in her arms and legs, tingling (pins and needles) sensation in four limbs, problems with bladder control and insomnia. In December 2017, the patient came for a routine check with her complaint of tingling (pins and needles) sensation in her four limbs and insomnia. Neurological examination revealed a horizontal gaze-evoked nystagmus. There was smoothness of the left nasolabial fold. The patient had upper-level motor weakness in her four extremities scale scores of 4,5b proximally and 4,5b distally with mild spasticity, hyperreflexia and pathological reflexes of Hoffmann in the left hand and Babinski in both lower limbs. She had problems with the heel-to-shin test, loss of balance, and following sensory impairments: Paresthesia, numbness, and positive Romberg's test. Cognitive and emotional abnormalities in our patient included a fluctuating hyperactive state. The results of the data on EAV readings with erythromycin (100 mg tablets) placed into the honeycomb of the EAV device in December 2017 are presented in (Table 2).

Table 2. Results of medicament testing after the fourth session of exposure.

As can be seen from the presented data, a negative response to erythromycin tablet testing was recorded at all tested measurement points.

On her next visit on 17.03.2018, she experienced an exacerbation of the disease over the last week. She recalled that one month ago, she got sick with influenza after contact with the diseased child. That time, she complained of weakness in her left leg, which drastically increased over three days and unsteady gait. Neurological examination showed a horizontal gaze-evoked nystagmus. The patient had upper-level motor weakness in her four extremities scale scores of 3,0b proximally and 3,5b distally with mild spasticity, hyperreflexia, and pathological reflexes of Hoffmann in the left hand and Babinski in both lower limbs. She had problems with the heel-to-shin test, ataxic gait, loss of balance, and following sensory impairments: Paresthesia, numbness, and positive Romberg's test. Cognitive and emotional abnormalities in our patient included a fluctuating hyperactive state with mild agitation.

Taking into account the patient's medical history and the presence of HSV1/2 IgG Ab, it was decided to conduct MT at the same measuring points using the nosode of DNA polymerase in 30 C dilution, nosode of Herpes simplex in 30 C dilution, and acyclovir (200 mg, tablets). The results of EAV readings made at that time are presented in Table 3

Table 3. Results of medicament testing before the fifth session of exposure.

Pre-test readings are given as the final result of the device readings obtained after the indicator drop. EAV post-test readings reflect the results obtained after medicament testing using the proposed drugs at the specified measuring points. As can be seen from the presented data, a positive response to medicament testing for the proposed drugs were obtained only at measuring point Ne3. We decided to use acyclovir for the exposure to the patient and performed the procedure described above. The procedure was carried out during which the emitter of the DTI with the drug acyclovir (200 mg) placed inside it was placed over the projection of various parts of the brain. Her condition improved within one week of the procedure: All described complaints disappeared. There were no visible changes in her neurological status. The results of the data on EAV readings with acyclovir (200 mg, tab) placed into the honeycomb of the EAV device in April 2018 are presented in Table 4.

Table 4. Results of medicament testing after the fifth session of exposure.

As can be seen from the presented data, a negative response to acyclovir testing was recorded at all tested measurement points. Thus, the patient received five exposure sessions using a “device to transfer information to the patient’s body” over the following years: 2017 and 2018. She had had no exacerbation of the disease from April 2018 till January 2024. The patient was subjected to an annual routine examination for possible exacerbation of the process, but the patient's condition and neurological status have gradually improved. In her last routine visit on 3.01.2024, the patient’s only complaint was the slight tingling in her hands. The neurological examination revealed normal cranial nerve conditions. There were no signs of upper-level motor damage. She had a positive Hoffmann's reflex in the left hand. The Babinski sign was absent on both feet. There were no signs of sensory impairments as well as the cerebellar signs. The only sign was slight difficulty in performing a heel-to-toy walking test. There were no signs of emotional instability. Our patient did not take prednisolone (tab) for the last five years. She continues to work as a musician and plays the piano. The patient teaches at a music school and leads an active social life. Figure 2 demonstrates the localization of the demyelinating lesions in different parts of the brain and the dynamic of changes accompanying the treatment according to the T2 weighted longitudinal MRI conducted from 2018 to 2023.

Figure 2: Localization of the demyelinating lesions in different parts of the patient's brain.

Discussion

The Russian patent describes the invention of scientists from the Siberian Branch of the Russian Academy of Sciences, which describes the cases of “Transfer of information from insulin to the human body” and “Transfer of information from an adrenaline solution to the human body” presented as information confirming the possibility of manifestation of this phenomenon. In both cases, drugs were used in liquid form (in ampoules) [8]. The monographs describe the results of in vitro and in vivo studies of the properties of the “device for transmitting information from the drug to the human body” [9,10]. A feature of the field formed inside the cylinder included in the described device is its deep penetrating ability. The nature of the physiological basis of the phenomenon of medicament testing has not yet been revealed. However, some scientists have expressed the idea that medicines in the human body realize themselves not only at the pharmacological level but also at the level of their inherent electromagnetic radiation [9]. The basis for such a statement was the achievements of quantum mechanics -the physical basis of which is wave-particle dualism, according to which any material object-particle or wave-has both wave and corpuscular properties [11]. According to the article’s author’s opinion, the mechanism for transferring information from a drug to the human body in a “device for transferring information from a drug to the human body” is very similar to the mechanism of medicament testing itself and can be explained as follows: Under the influence of a weak electromagnetic field formed inside the cylinder of the device, when the laser device is switched on, the molecules of chemical elements that make up the drug begin to activate [6]. The activation of the molecules causes them to vibrate and fluctuate. This, in turn, leads to the formation of a specific field inherent in the overall structure of the drug or, in other words, to the formation of an electromagnetic imprint of the crystal lattice of the chemical structure of the organic substance (drug) placed inside the emitter (cylinder). Since the direction of the waveguide located on the outer wall of the cylinder goes from top to bottom, then the vector of field motion inside the cylinder is also directed from top to bottom, which in turn leads to the transfer of the formed imprint downwards along the direction of the cylinder field vector. And then, apparently, the drug's resulting electromagnetic imprint interacts with the biological object's electromagnetic field characteristic over the projection of which the emitter (cylinder) is placed. This statement requires rigorous proof. The study of the spectral characteristics of the molecules of chemical elements included in the composition of pharmacological drugs is the basis of the method of IR spectroscopy in pharmacy. It is based on the absorption of electromagnetic radiation in the infrared range by the molecules of the drug under study, in which the vibrational and rotational states of the medicine's molecules are excited [12]. One of the reflections of the chemical processes occurring in cells is Ultra-weak Radiation (USR), which is inherent in all biological systems. The first data on the presence of weak ultraviolet radiation accompanying exothermic chemical reactions occurring both in various living tissues and in vitro were described in the works of Gurvich,1923 [13]. The presence of distant interactions has been demonstrated in cell and organ cultures of animals, plant tissues, bacteria, and embryos of lower vertebrates. Electromagnetic radiation from most biological objects has very low intensity, according to F.-A. Popp, the power of electromagnetic interaction of biological objects lies in the range of 10-17-10-15 W (equivalent to ~100-103 quantum/sec in the near UV-near IR range) [14-19]. It is known about the effects of low-level laser light on biochemical and cellular function include cellular metabolic activation and increased functional activity (ATP synthesis is increased by up to 150%), stimulation of repair processes as a result of increased cell proliferation, anti-inflammatory effects, microcirculation activation, and more efficient tissue metabolism; analgesic effects as a result of increased endorphin release; immune-stimulation with correction of cellular and humoral immunity, increased antioxidant activity in the blood, staining lipid peroxidation in cell membranes; stimulation of erythropoiesis, vasodilatation, normalization of acid-base balance in the blood, reflexogenic effects on the functional activity of different organs and systems and others [4]. The selection of the drugs in this study was based on the laboratory test data. Erythromycin belongs to the group of macrolides and is active against gram-positive microorganisms, which include β-hemolytic streptococcus. Acyclovir is an antiviral drug and is active (including) against herpes virus infection. Both drugs were tested in the process of medicament testing before application and the decision to use them was based on a positive response to medicament testing.

The positive result that was obtained suggested the transfer of information from drugs to the patient’s body when using these drugs in the formed field of the DTI and showed the occurred interaction of the electromagnetic imprint of the crystal lattice of the chemical structure of the drug with the electromagnetic radiation, reflecting the wave characteristics of infections (β-hemolytic streptococcus and herpesvirus infection) in those tissues of the body that were exposed: Tonsils, paranasal sinuses, deep cervical lymph nodes: β-hemolytic streptococcus; and the brain: β-hemolytic streptococcus and herpesvirus infection. This statement requires further research. Previously obtained results on using the proposed device to treat various diseases were published and reported at conferences [20,21]. This message, for the first time, brings to readers' attention the successful results of studies conducted on a patient with a severe nervous system pathology, which is multiple sclerosis. According to the patient, this type of treatment compares favorably with previous therapy in terms of the speed of onset of the effect obtained, the absence of side and adverse effects, as well as the rapid resolution of almost all symptoms of the disease, which allows her to continue working as a musician and lead an active social lifestyle.

Conclusion

The results of the study demonstrated the positive effect of using a “device for remote transfer of information from a drug to the human body” in the form of cessation of disease activity, prevention of the growth of neurological manifestations of the disease and positive dynamics of demyelinating lesions in the brain of a patient with multiple sclerosis, which allowed the patient to continue working as a musician and lead an active social life. This type of exposure is characterized by rapidity of action, safety, and the absence of side effects from the therapy.

References

1. Hye-Ok K, et al. Significant associations of PAI-1 genetic polymorphisms with osteonecrosis of the femoral head. BMC Musculoskelet Disord. 2011;12:160.

   [Crossref] [Google Scholar] [PubMed]

2. Assouline-Dayan Y, et al. Pathogenesis and natural history of osteonecrosis. In: Seminars in Arthritis and Rheumatism. Semin Arthritis Rheum. 2002;94-124. 

   [Google Scholar] [PubMed]

3. Kim TH, et al. Lack of association of MTHFR gene polymorphisms with the risk of osteonecrosis of the femoral head in a Korean population. Mol Cells. 2010;29:343-348.

   [Crossref] [Google Scholar] [PubMed]

4. Cui L, et al. Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China. Int Orthop. 2016;40:267.

   [Crossref] [Google Scholar] [PubMed]

5. Larson E, et al. Early-stage osteonecrosis of the femoral head: where are we and where are we going in year 2018? Int Orthop. 2018;42:1723-1728.

   [Crossref] [Google Scholar] [PubMed]

6. Yeh YA, et al. Association of traditional chinese medicine therapy with risk of total hip replacement in patients with nontraumatic osteonecrosis of the femoral head: a population-based cohort study. Evid Based Complement Alternat Med. 2019;2019:5870179.

   [Crossref] [Google Scholar] [PubMed]

7. Zhang XY, et al. Icariin regulates miR-23a-3p-mediated osteogenic differentiation of BMSCs via BMP-2/Smad5/Runx2 and WNT/β-catenin pathways in osteonecrosis of the femoral head. Saudi Pharm J. 2021;29:1405-1415.

   [Crossref] [Google Scholar] [PubMed]

8. Fang B, et al. Huo Xue Tong Luo capsule ameliorates osteonecrosis of femoral head through inhibiting lncRNA-Miat. J Ethnopharmacol. 2019;238:111862.

   [Crossref] [Google Scholar] [PubMed]

9. Zhao J, et al. Therapeutic effects of low-frequency phonophoresis with a Chinese herbal medicine versus sodium diclofenac for treatment of knee osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Tradit Chin Med. 2016;36:613-617. 

   [Google Scholar]

10. Yuan H, et al. Research progress on chemical constituents and quality control of Epimedii Folium. Zhong Cao Yao. 2014;45:3630-3640. 

    [Google Scholar]

11. Zeng Y, et al. Icariin and its metabolites as potential protective phytochemicals against cardiovascular disease: From effects to molecular mechanisms. Biomed Pharmacother. 2022;147:112642.

    [Crossref] [Google Scholar] [PubMed]

12. Shi Y, et al. Identifying the anti-metastasis effect of Anhydroicaritin on breast cancer: Coupling network pharmacology with experimental validation. J Ethnopharmacol. 2022;293:115326.

    [Crossref] [Google Scholar] [PubMed]

13. Cho WK, et al. Antiviral activity of epimedium koreanum nakai water extract against influenza viruses. Biomed Pharmacother. 2022;146:112581.

    [Crossref] [Google Scholar] [PubMed]

14. Zheng Y, et al. Icariside II inhibits lipopolysaccharide-induced inflammation and amyloid production in rat astrocytes by regulating IKK/IκB/NF-κB/BACE1 signaling pathway. Acta Pharmacol Sin. 2020;41:154-162.

    [Crossref] [Google Scholar] [PubMed]

15. Huang J, et al. Icariside II attenuates methamphetamine-induced neurotoxicity and behavioral impairments via activating the keap1-nrf2 pathway. Oxid Med Cell Longev. 2022;2022:8400876.

    [Crossref] [Google Scholar] [PubMed]

16. Hu L, et al. Icariin inhibits isoproterenol-induced cardiomyocyte hypertropic injury through activating autophagy via the AMPK/mTOR signaling pathway. Biochem Biophys Res Commun. 2022;593:65-72.

    [Crossref] [Google Scholar] [PubMed]

17. Ding Y, et al. Improvement of solubility and pharmacokinetic profile of hepatoprotector icariin through complexation with HP-γ-cyclodextrin. Front Pharmacol. 2023;14:1138686.

    [Crossref] [Google Scholar] [PubMed]

18. Wishart DS, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:668-672.

    [Crossref] [Google Scholar] [PubMed]

19. Wall L. PERL- Practical Extraction and Report Language. 1991.
20. Montojo J, et al. GeneMANIA: Fast gene network construction and function prediction for cytoscape. F1000res. 2014;3:153.

    [Crossref] [Google Scholar] [PubMed]

21. Yang C, et al. Tongluo shenggu capsule promotes angiogenesis to ameliorate glucocorticoid-induced femoral head necrosis via upregulating VEGF signaling pathway. Phytomedicine. 2023;110:154629.

    [Crossref] [Google Scholar] [PubMed]

22. Moriishi T, et al. Overexpression of BCLXL in osteoblasts inhibits osteoblast apoptosis and increases bone volume and strength. J Bone Miner Res. 2016;31:1366-1380.

    [Crossref] [Google Scholar] [PubMed]

23. Zhang Q, et al. PTGS2 identified as a biomarker of glucocorticoid-induced osteonecrosis of the femoral head and an enhancer of osteogenesis. Genes Dis. 2023;10:14-17.

    [Crossref] [Google Scholar] [PubMed]

24. Xia Q, et al. miR-125a-5p-abundant exosomes derived from mesenchymal stem cells supp ress chondrocyte degeneration via targeting E2F2 in traumatic osteoart hritis. Bioengineered. 2021;12:11225-11238.

    [Crossref] [Google Scholar] [PubMed]